Ya, that article was crap. I responded to their

Ya, that article was crap. I responded to their article with this.. But noticed approvals are on, so most likely will not be approved.

"Think about this...

Here are the FACTS:
FDA is requiring safety data from the last group of 700mg patients.
FDA already knows efficacy is at 92% and rising on 700mg
FDA already knows efficacy is at 95% with 525mg
FDA already knows efficacy is around 70% on 350mg
FDA already knows Leronlimab / Pro140 has NO SAE's - THIS IS HUGE seeing as though there are open lawsuits against GILD for side effects related to NASH!
NP in one of his statements says, "You will understand the reason for delay soon."

Now lets ask ourselves....

If FDA already has safety data for 525mg and knows it is 95% why are they requiring 700mg safety data? Especially when efficacy of competing drugs are only in the 40% range...

My opinion on this,

Occupancy Test and Combo Therapy will be approved almost instantly with these results, mono will be approved right after the 2nd Phase 3 trial is complete or possibly even sooner with all 3 doses approved with occupancy testing required.

If cancer results are positive like in animal studies, with over 98% metastasis reduced and tumor shrinkage 40% to 60% - This could be approved for use in less than a couple months with off-label use for HIV mono and all the indications that "YOU" state are like "tilting at windmills".

With Samsung heading the manufacturing of this drug, the science behind it, the no side effects portion, the proven efficacy in over 800 patients, no resistances to the drug in over 5 years, multiple indications on Cancer, NASH, GvHD, MS, Hashimotos, Lupus, Diabetes, HIV, Stroke, arthritis, and many others, only a fool, or a person with ulterior motives would write an article like this. When they get to BLA the NBA with another company kicks in and they will have 90 million to play with +50% royalties on licensing agreements. There is also something in the works for "possible" binding licensing agreement for U.S only by EOM. Shorting this is like playing with dynamite with a short fuse at this point of the game.

Maybe you should take a little time off of trying to manipulate the stock, and actually read up on CCR5 and its many affects on the human body.

And if we are quoting articles, lets just say "13 shots on goal" was definitely a better read."